The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...
FIT-001 enrolled ccRCC patients with prior immunotherapy, KPS ≥70, and prior cabozantinib exposure, using darlifarnib 3/5/8 mg QD (7-on/7-off) plus cabozantinib 40/60 mg. Antitumor activity was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results